Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE. Issue 6 (15th January 2021)

• Record Type: Journal Article
• Authors: Schilling, Richard; Dhillon, Gurpreet Singh; Tondo, Claudio; Riva, Stefania; Grimaldi, Massimo; Quadrini, Federico; Neuzil, Petr; Chierchia, Gian-Battista; de Asmundis, Carlo; Abdelaal, Ahmed; Vanderlinden, Liesbeth; Tan, Tiffany; Ding, Wern Yew; Gupta, Dhiraj; Reddy, Vivek Y
• Is Part Of: Europace. Volume 23:Issue 6(2021)
• Page Start: 851
• Page End: 860
• Publication Date: 2021-01-15
• Subjects: Atrial fibrillation -- Radiofrequency ablation -- Pulmonary vein isolation -- Electrophysiological mapping -- Radiofrequency balloon catheter -- Quality of life; Arrhythmia -- Treatment -- Periodicals; Cardiac pacing -- Periodicals; Catheter ablation -- Periodicals; Heart -- Physiology -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1093/europace/euaa382
• Languages: English
• ISSNs: 1099-5129

Abstract

Abstract: Aims: To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used with a multi-electrode diagnostic catheter for pulmonary vein isolation (PVI). Methods and results: This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over 12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of ≥1 PVs after adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One patient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was 72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all AFEQT subscale scores were seen at 6 and 12 months. Conclusion: PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clinically meaningful improvement in quality of life. ClinicalTrials.gov Registration Number: NCT03437733. Graphical Abstract: